Life after uterine cancer;La vie après un cancer de l'utérus

Revue du Praticien

Volumn 64, Issue 6, 2014, Pages 816-820

  Koskas, Martin ^a,b   Rodier, Jean Michel ^a   Bretel, Jean Jacques ^a   Bonneau, Claire ^c   Luton, Dominique ^a,b   Touboul, Cyril ^d   Rouzier, Roman ^c  

^a BICHAT HOSPITAL   (France)

^b Risques Cliniques et Securite en Sante des Femmes et en Sante Perinatale   (France)

^c INSTITUT CURIE   (France)

^d CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER STAGING; ENDOMETRIUM CANCER; FERTILITY PRESERVATION; FOLLOW UP; HUMAN; RADIATION DOSE; REVIEW; SECOND CANCER; SEXUAL DYSFUNCTION; UTERINE CERVIX; UTERINE CERVIX CANCER; UTERUS CANCER;

ANTINEOPLASTIC AGENTS; CONTINUITY OF PATIENT CARE; FEMALE; FERTILITY PRESERVATION; HUMANS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; POSTOPERATIVE COMPLICATIONS; RADIOTHERAPY; SEXUALITY; UTERINE NEOPLASMS;

EID: 84903842578     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (11)

1. Koskas M, Bendifallah S, Luton D, Darai E, Rouzier R. Independent external validation of radiotherapy and its impact on the accuracy of a nomogram for predicting survival of women with endometrial cancer. Gynecol Oncol 2011;123:214-20.
2. Querleu D, Planchamp F, Narducci F, et al. Clinical practice guidelines for the management of patients with endometrial cancer in France: recommendations of the Institut national du cancer and the Société française d'oncologie gynécologique. Int J Gynecol Cancer 2011;21:945-50.
3. Brown AP, Neeley ES, Werner T, Soisson AP, Burt RW, Gaffney DK. A population-based study of subsequent primary malignancies after endometrial cancer: genetic, environmental, and treatment-related associations. Int J Radiat Oncol Biol Phys 2010;78:127-35.
4. Hursting SD. Obesity, energy balance, and cancer: a mechanistic perspective. Cancer Treat Res 2014;159:21-33.
5. Zanagnolo V, Ming L, Gadducci A, et al. Surveillance procedures for patients with cervical carcinoma: a review of the literature. Int J Gynecol Cancer 2009;19:194-201.
6. Chaturvedi AK, Engels EA, Gilbert ES, et al. Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. J Natl Cancer Inst 2007;99:1634-43.
7. Nomura H, Aoki D, Takahashi F, et al. Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG 2041). Ann Oncol 2011;22:636-42.
8. Wagner A, Jhingran A, Gaffney D. Intensity modulated radiotherapy in gynecologic cancers: hope, hype or hyperbole? Gynecol Oncol 2013;130:229-36.
9. Juraskova I, Butow P, Bonner C, Robertson R, Sharpe L. Sexual adjustment following early stage cervical and endometrial cancer: prospective controlled multi-centre study. Psychooncology 2013;22:153-9.
10. Koskas M, Bendifallah S, Luton D, Darai E, Rouzier R. Safety of uterine and/or ovarian preservation in young women with grade 1 intramucous endometrial adenocarcinoma: a comparison of survival according to the extent of surgery. Fertil Steril 2012;98:1229-35.
11. Koskas M, Yazbeck C, Walker F, et al. Traitement conservateur du cancer et des hyperplasies atypiques de l'endomètre en vue de préserver la fertilité: revue de la littérature. Bull Cancer 2012;99:51-60.